Genuine Touch, Lasting Glow

CellREDM™

Essence, infused within.



HANS BIOMED

CellREDM™

Formulated with advanced extracellular matrix (ECM) components, this high-purity ADM skin booster helps reinforce the skin's structural framework and supports comprehensive improvement in dermal density, elasticity, and texture through the synergistic activity of collagen, elastin, and glycosaminoglycans (GAGs) delivered in a micro-particle form.


01
ECM Components
Advanced ECM-based, high-purity ADM skin booster supporting the skin's intrinsic structural framework

02
Micro-particle
ADM powder with micro-sized particles (<75 μm)

03
Multi-component Composition
ECM-rich composition with collagen, elastin, and GAGs

04
High biocompatibility & safety
Reduced risk of immune response, rejection, and inflammatory reactions

05
Clinically proven result
Clinical evaluation confirmed improvements in skin texture, tone, deep hydration, density, and elasticity after treatment.



20 Years of Proven Expertise

Since establishing Korea's first MFDS-approved tissue bank in 2005, we have accumulated 20 years of expertise in advanced biomaterial processing, with AATB and FDA certifications ensuring exceptional precision and safety.

Award-Winning Quality Innovation Product

Recognized by the Korean Government's National Quality Innovation Competition for excellence in manufacturing innovation, reliability, and customer value.




조직은행설립허가증

허가번호	제 1 호		
조직은행의 명칭	한스바이오메드㈜		
조직은행의 주소	대전광역시 유성구 유성대로1628번길 64 (전민동)		
대표자 성명	김근영	생년월일	1977 년 09 월 03 일
조직은행의 장 성명	박성오	생년월일	년 월 일
의료관리자 성명	전병찬	면허종별/면허번호	의사/20149
조직은행 유형	조직가공처리업자, 조직수입업자		
조직은행 업무구분	저장, 처리, 보관, 분배, 수입		
조직취급품목	뼈, 연골, 근막, 피부, 인대, 건		
허가유효기간	2022 년 01 월 02 일 부터 2026 년 01 월 01 일 까지		

「인체조직안전 및 관리 등에 관한 법률」 제13조제1항 전단 및 제14조제2항과 「인체조직안전에 관한 규칙」 제5조제3항 및 제8조제1항에 따라 위와 같이 허가합니다.

2022 년 12 월 28 일

대전지방식품의약품안전청장



American Association of Tissue Banks

Herewith certifies
that the Institution named here
Hans Biomed Corporation
Yuseong-gu, Daejeon
has met the Association's accreditation requirements
and is hereby accredited for

Deceased Donor	Authorization	Donor Screening	Recovery	Processing or Preparation	Donor Eligibility Determination	Storage	Distribution
Cardiac Tissue							
Cellular Tissue							
Musculoskeletal Tissue				✓	✓	✓	✓
Skin				✓	✓	✓	✓
Vascular Tissue							
Non-Transplant Anatomical (Male or Female)							
Living Donor	**Informed Consent**	**Donor Screening**	**Recovery or Acquisition**	**Processing**	**Donor Eligibility Determination**	**Storage**	**Distribution**
Autologous Tissue							
Birth Tissue							
Reproductive Tissue							
Surgical bone							

In witness whereof the undersigned officers, being duly authorized, have caused this Certificate to be issued and the Corporate Seal of this Association to be affixed hereon this the 16th day of January 2025

Chair, Board of Governors

Expiration Date: January 16, 2028
Accreditation #: 00207



FDA U.S. FOOD & DRUG ADMINISTRATION

FDA Home Page | Contact eHCTERS Technical Support

HUMAN CELL AND TISSUE ESTABLISHMENT REGISTRATION - Public Query
Establishment Details

Establishment Name and Location

Current Status:	Registered
Last Annual Registration Year:	2025
FDA Establishment Identifier (FEI):	3003828812
Establishment Name:	Hans Biomed Corporation
Address:	64, yuseong-daero 1628 beon-gil
	Youseong-gu
City:	Daejeon
State:	
Zip:	34054
Country:	KOREA, SOUTH
Foreign Phone:	
Phone:	822-466-2266
Satellite Recovery Establishment:	Yes
Parent Manufacturing Establishment FEI No.:	3003828812

Establishment Functions

Types of HCT/Ps	Recover	Screen	Donor Testing	Package	Process	Store	Label	Distribute
Amniotic Membrane								
Blood Vessel								
Bone		☑		☑	☑	☑	☑	☑
Cardiac Tissue - non-valved								
Cartilage								
Cornea								
Dura Mater								

< Korea's First MFDS-Approved Tissue Bank > < AATB-Certified > < USA FDA-Registered >

ECM Components


CellREDM™ is formulated with advanced ECM (extracellular matrix) components, offering excellent tissue compatibility and promoting natural responses aligned with the skin's regenerative cycle and physiological rhythms, leading to predictable and reliable rejuvenation effects.

	Skin Booster (General)	CellREDM™	Collagen Booster
Origin	Synthetic ingredient–based product	ECM-based products	Animal-derived product
Main Components	Synthetic polymers / nucleic acids / protein-based	ECM composite components (Collagen + Elastin + GAGs)	Purified single collagen (atelocollagen)
Mechanism of Action	Cell activation / growth factor expression / inflammation-mediated regeneration	ECM remodeling and restoration of the fibroblast environment	Primarily collagen supplementation
Biocompatibility	Moderate (inflammation-based reactions possible)	High (minimal immune response)	Low–moderate (immune reaction caution needed)

Micro-particle

Tissue-Friendly Absorption and Treatment Safety


Processed into ultra-fine particles smaller than 75 μm, it disperses naturally within the skin tissue, enabling uniform and stable absorption. This minimizes post-procedure complications such as swelling or nodules and supports faster recovery.



Multi-component Composition

Synergistic Complex of Collagen, Elastin, and GAGs

Multi-component formulation goes beyond simple hydration to enhance skin density, improve elasticity, and reduce fine lines. By stimulating fibroblast activity, it supports gradual and natural skin structure recovery through intrinsic regeneration, making it a comprehensive ECM-based skin booster.



Assessment of cell removal post-decellularization


Cellular components and nucleic acids (DNA and RNA)
that may trigger immune responses have been effectively removed.

Visualizing the structure of cells and tissue

by staining them with different colors within the sample.(Cells: purple, Tissue: pink)


H&E

BEFORE



Numerous cells are present within the tissue.

AFTER



Cells are removed, leaving only the tissue structure.

Tissue analysis method: H&E (Hematoxylin & Eosin staining

Visualizing the structure of cells and tissue

by binding DAPI to nuclear DNA, which fluoresces blue.(Cells: blue)


DAPI

BEFORE



Many cells are present, showing widespread blue fluorescence.

AFTER



Cells are almost completely removed; blue fluorescence is barely visible.

Tissue analysis method: DAPI staining




High biocompatibility & safety

Assessment of dsDNA residue in decellularized tissue

Cellular components and nucleic acids (DNA and RNA)
that may trigger immune responses have been effectively removed.

Objective

Detecting and quantifying dsDNA in CellREDM™ raw material via colorimetric response using an analytical kit.



Result

Cells are nearly removed, resulting in a very low residual dsDNA content.


In vitro Cytotoxicity Test


CellREDM™ was evaluated in vitro to assess cell compatibility with the processed tissue.

Cytotoxicity Test			
Test Group	Negative (Not treat)	Positive (DMSO)	CellREDM™
Result	100% viability	3.20% viability	85.70% viability

Result

The processed CellREDM™ donor, with immunogenic components removed, showed high cell viability, demonstrating high compatibility.





Cytotoxicity Test

Cytotoxicity can be analyzed using qualitative or quantitative methods, with quantitative assessment being the preferred approach.
In quantitative evaluation, a decrease in cell viability of 30% or more is considered indicative of cytotoxicity.

Reference Standard : ISO 10993-5:2009

Clinical evaluation results

CellREDM™ was found to improve skin texture, skin tone, elasticity, deep hydration, and dermal density at all evaluation points at 1 week, 2 weeks, and 4 weeks after treatment.

- In the efficacy questionnaire, 100% of participants responded positively for all evaluation items at 1, 2, and 4 weeks post-treatment.
- No adverse skin reactions were observed in any participants throughout the study period.

Skin Texture Improvement +14.71%

Deep Hydration Improvement +10.90%



Dermal Density Improvement +11.79%


Skin Tone Improvement +5.34%

Skin Elasticity Improvement +19.31%

Clinically proven result

Skin Texture Improvement


Skin texture improved by 14.71% at 4 weeks after treatment, compared to baseline.



Before Treatment | 1 Week After | 2 Weeks After | 4 Weeks After

Skin Tone Improvement


Skin tone improved by 5.34% at 4 weeks post-treatment, compared to baseline.



Before Treatment | 1 Week After | 2 Weeks After | 4 Weeks After

Dermal Density Improvement

Dermal density improved by 11.79% at 4 weeks post-treatment, compared to baseline.




Before Treatment | 1 Week After | 2 Weeks After | 4 Weeks After

*Measurement & evaluation conducted by:
Skin Clinical Imaging Center


Skin Elasticity Improvement

Skin elasticity improved by +19.31% at 4 weeks post-treatment, compared to baseline.




Deep Hydration Improvement

Deep skin hydration improved by +10.90% at 4 weeks post-treatment, compared to baseline.



• How to use •

CellREDM™ Guide

	Gauge	N/S	HA	Lidocaine
Needle 	33G or 34G	4ml	2ml	1ml
Cannula 	23G or 25G			

CellREDM™ Preparation Materials

CellREDM™, N/S, Non-Crosslinked HA, Lidocaine, 33G Needle or **34G Needle**

*Preparing an additional 10 cc syringe can be helpful during setup.

CellREDM™ Procedure Steps

1. Prepare 4 cc of saline.
2. Pull back the plunger of the syringe containing CellREDM™ Powder by approximately 0.2–1 cc.
3. Tap the syringe gently to loosen any clumped powder.
4. Attach the adapter and inject 4 cc of saline into the CellREDM™ Powder syringe.
5. Hold one syringe in each hand and alternate pushing the plungers back and forth slowly (at least 20 times) until fully hydrated.
6. Mix the fully hydrated CellREDM™ with 2 cc of non-crosslinked HA.
7. Mix the combined solution with 1 cc of lidocaine.
8. Dispense the fully mixed CellREDM™ into 1 cc syringes for injection.

* Pulling the powder toward the back space first helps create room for hydration and improves mixing efficiency.
* If excessive foam forms during hydration, eliminate the empty space inside the syringe, then resume mixing.
* If air bubbles remain, push the plunger upward to remove them.
  (If they cannot be removed easily, loosen the adapter slightly.)







• SPECIFICATION •



Product Name	CellREDM™
Classification	Human allogenic tissue, Acellular Dermal Matrix (Injectable/Powder)
Ingredients	Collagen, GAGs, elastin — components derived from dermal matrix
Particle Size	<75 μm
Package Contents	Allogenic dermal collagen, 1 mixing syringe, 2 adapters, 3 needles
Sterilization	E-Beam sterilization
Volume	160mg
Precautions	Single-use only; do not reuse or re-sterilize
Storage Conditions	Store at room temperature (1–30°C)
Shelf Life	36 months from the date of manufacture
Expected Effects	Improvement of pore size, pigmentation/freckle reduction, skin texture enhancement, skin elasticity improvement

HANS BIOMED
Hans Building, 7 Jeongui-ro 8-gil, Songpa-gu, Seoul
TEL. 02-466-2266 / www.hansbiomed.com